Interview with Per Jansson, CEO of Vicore Pharma

Redeye published an interview with Per Jansson, CEO of Vicore Pharma.

Redeye published an interview with Per Jansson, CEO of Vicore Pharma.

View the interview via Redeyes homepage.

Nina Carlén, IR, Communication & Administration coordinator
Tel: 0763-90 94 04 eller e-mail: 

About Vicore Pharma Holding
Vicore Pharma, a Nasdaq Stockholm First North listed holding-, and management company. Vicore Pharma develops drugs targeting stimulation of the AT2 Receptor (AT2R) in the Renin-Angiotensin-System (RAS). The company vision is to establish AT2-agonists as a new effective class of small molecule drugs. Our lead candidate, C21 will be focused on the indication Idiopatic pulmonary fibrosis (IPF). For further information, please refer to

Vicore Pharmas share is listed on NASDAQ Stockholm, First North under the ticker VICO. The company´s Certified Adviser is Redeye AB.

About Us

Vicore Pharma develops drugs that act through the AT2 receptor. The company’s drug candidate C21 aims to improve the treatment of idiopathic pulmonary fibrosis, a rare disease for which C21 has been granted orphan drug designation both in the EU and the US. In addition, C21 is explored pre-clinically in a number of rare diseases where the AT2 receptor plays an important role. Vicore Pharma is based in Astra Zeneca's Bioventurehub in Mölndal. The company's share (VICO) is listed for trading on Nasdaq First North in Stockholm with Erik Penser Bank as Certified Adviser. For more information, see